NVRO vs. OFIX, OSUR, IRMD, SKIN, SRDX, ANIK, PLSE, NPCE, TCMD, and BVS
Should you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Orthofix Medical (OFIX), OraSure Technologies (OSUR), Iradimed (IRMD), Beauty Health (SKIN), Surmodics (SRDX), Anika Therapeutics (ANIK), Pulse Biosciences (PLSE), NeuroPace (NPCE), Tactile Systems Technology (TCMD), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Orthofix Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
In the previous week, Orthofix Medical had 5 more articles in the media than Nevro. MarketBeat recorded 6 mentions for Orthofix Medical and 1 mentions for Nevro. Orthofix Medical's average media sentiment score of 1.34 beat Nevro's score of 0.12 indicating that Nevro is being referred to more favorably in the news media.
Orthofix Medical has a net margin of -20.28% compared to Orthofix Medical's net margin of -21.69%. Nevro's return on equity of -10.63% beat Orthofix Medical's return on equity.
Nevro received 94 more outperform votes than Orthofix Medical when rated by MarketBeat users. Likewise, 66.10% of users gave Nevro an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by company insiders. Comparatively, 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Nevro has lower revenue, but higher earnings than Orthofix Medical. Nevro is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
Orthofix Medical presently has a consensus price target of $15.50, indicating a potential upside of 19.32%. Nevro has a consensus price target of $21.23, indicating a potential upside of 87.55%. Given Orthofix Medical's higher probable upside, analysts plainly believe Nevro is more favorable than Orthofix Medical.
Summary
Nevro beats Orthofix Medical on 9 of the 17 factors compared between the two stocks.
Get Nevro News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
